Novartis Starts Trial for ASA404 in Lung Cancer
Novartis’ nonsmall cell lung cancer drug ASA404, which is designed to selectively reduce blood supply to tumors, has entered a Phase III trial.
The randomized, double-blind, placebo-controlled, multicenter ATTRACT-1 study will evaluate ASA404 in combination with paclitaxel and carboplatin as a first-line treatment for locally advanced or metastatic nonsmall cell lung cancer.
This entry was posted on Wednesday, April 16th, 2008 at 1:36 pm and is filed under Research, Non-Small-Cell. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.